Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220008387METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY USING 3,3'-DIINDOLYLMETHANE
US 13.01.2022
Int.Class A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
Appl.No 17303353 Applicant Boulder BioScience LLC Inventor Michael A. Zeligs

Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane.

2.WO/2022/006667DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NON-CODING RNAS AS TARGETS
WO 13.01.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/CA2021/050924 Applicant THE UNIVERSITY OF WESTERN ONTARIO Inventor CHAKRABARTI, Subrata
Method of identifying a subject as having an increased likelihood of progressing to end-organ damage due to diabetes comprising comparing the amount of a lncRNA in a sample from the subject with a reference value, and if the amount of the lncRNA in the sample is increased relative to the reference value, identifying the subject as having an increased probability of progressing to end-organ damage due to diabetes. The lncRNA is one or more of HOTAIR, H19, WISPER, ZFAS1, HULC, ANRIL, MALAT1, MIAT, and MEG3. Also methods of treating chronic diabetic complications and other conditions comprising administering a HOTAIR inhibitor.
3.WO/2022/007807BISPECIFIC ANTIBODY AND USE THEREOF
WO 13.01.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/104810 Applicant BIO-THERA SOLUTIONS, LTD. Inventor LIANG, Shizhong
Provided are a bispecific antibody and use thereof. The bispecific antibody or antigen binding fragment can bind to two antigens or two epitopes of the same antigen. The antibody or antigen binding fragment can be used for treating various diseases, such as inflammatory diseases, autoimmune diseases, cancer or spinal cord injury, and can also be used for the diagnosis and prognosis of related diseases.
4.WO/2022/008902METHOD FOR TREATING A GD2-POSITIVE CANCER
WO 13.01.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/GB2021/051721 Applicant EUSA PHARMA (UK) LIMITED Inventor LODE, Holger Nikolaus
A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m2, and/or in a dose of up to 100 mg/m2 per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m2/day.
5.WO/2022/010912ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/040533 Applicant FLAGSHIP PIONEERING INNOVATIONS VI, LLC Inventor GRIGORYAN, Gevorg
The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g.,COVID-19).
6.20220009979FUSION PROTEINS AND METHODS OF TREATING COMPLEMENT DYSREGULATION USING THE SAME
US 13.01.2022
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No 17267308 Applicant Alexion Pharmaceuticals, Inc. Inventor Julian Chandler

Described herein are fusion proteins that include two fragments of factor H, a fragment of factor H and an Fc domain, or a fragment of factor H, a fragment of CR2, and an Fc domain. The use of such proteins in methods of treatment for diseases mediated by alternative complement pathway dysmegulation.

7.WO/2022/008027ANTIBODIES BINDING IGV OF IGSF11 (VSIG3) AND USES THEREOF
WO 13.01.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/EP2020/068964 Applicant IOMX THERAPEUTICS AG Inventor ZANTOW, Jonas
The invention is based on the surprising finding of antibodies that bind to an immunoglobulin-like (Ig) domain of the extra cellular domain (ECD) of IGSF11 (VSIG3) can also inhibit the interaction between IGSF11 and IGSF11 receptors such as VSIR (VISTA), the inhibition of such interaction can provide products, compositions and methods for treating diseases using antigen binding proteins targeting an Ig domain of IGSF11-ECD, including those being inhibitors of IGSF11-interaction with VSIR. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of cell-mediated immune responses, and/or to kill such cells and/or methods for treating proliferative diseases, using an IGSF11 inhibitor such as an antibody binding to an Ig domain of IGSF11-ECD, as well as certain related aspects including detection, diagnostic and screening methods.
8.WO/2022/010802METHODS FOR DETECTING AND TREATING INFECTION
WO 13.01.2022
Int.Class A61K 39/15
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
15Reoviridae, e.g. calf diarrhea virus
Appl.No PCT/US2021/040363 Applicant EICOSIS, LLC Inventor HAMMOCK, Bruce D.
The present disclosure provides methods for diagnosing and treating infection in a subject, as well as disorders that arise from infection and/or risk of severe infection. Also provided are systems to diagnose, prognose, monitor, profile, classify, and/or otherwise determine presence of a disease or disorder, such as pathogenic infection, as well as severity of such infections.
9.20220008359COMBINATION ANTI-CANCER PRODUCTS AND METHODS
US 13.01.2022
Int.Class A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
Appl.No 17370675 Applicant Ankh Life Sciences Limited Inventor Gene H. Zaid

Combination dosage forms of anti-cancer products include components a) and b), where component a) comprises individual amounts of curcumin, harmine, isovanillin, and component b) comprises an agent selected from the group consisting of EGFR inhibitors, CDK 4/6 inhibitors, 5-fluorouracil, checkpoint inhibitors, anti-metabolites, prodrugs thereof, and mixtures thereof. The products may be administered to mammalian subjects suffering from a variety of cancers, to provide a synergistic therapeutic effect.

10.WO/2022/008658METHOD FOR OBTAINING A COMPOSITION COMPRISING HUMAN PLASMA-DERIVED IMMUNOGLOBULIN M
WO 13.01.2022
Int.Class C07K 16/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
06from serum
Appl.No PCT/EP2021/069000 Applicant GRIFOLS WORLDWIDE OPERATIONS LIMITED Inventor LINDSAY, Myles
A method for preparing a composition of human plasma-derived immunoglobulin M (IgM) including the steps of (a) PEG precipitation of the IgM; (b) resuspension of the precipitated IgM; (c) performing an adsorption chromatography; (d) removing isoagglutinins A/B; (e) nanofiltration; and (f) ultrafiltration/diafiltration. In the method for preparing the composition, the precipitation step a) is preferably performed at a pH between 4.5 and 6.5, and the PEG is preferably at a concentration between 5 (w/v) and 11% (w/v).